DIZE Regulated the expressions of eNOS, ACE, and ACE2/MAS Axis
in SuPNx Rats
Figure 5A shows a representative pulmonary expression of eNOS, ACE,
ACE2, MAS by Western blot analysis. SuPNX42 has the
trend to upregulated pulmonary eNOS expression when compared with the
sham-operated rats. Pulmonary expression of eNOS was significantly
elevated in the early treatment protocol when compared with the
SuPNx42 groups, but this was not seen in the late
treatment protocol (Figure 5B).
Compared to the sham-operated rats, the ratio of pulmonary expression of
ACE was elevated in the SuPNx42 group. Significant
decreases in ACE protein expression in both early and late DIZE
treatment groups were noted when compared with the vehicle-treated
SuPNx42 rats. (Figure 5C)
Pulmonary expression of ACE2 was increased in the early treatment group
(SuPNX42/DIZE1–42) compared to the
SuPNx42 rats. No significant differences were found
among the sham42, SuPNx42, and
SuPNX42/DIZE29–42 groups (Figure 5D).
The Mas is a G protein-coupled receptor with its vasoprotective effect
in RAS system.14 In western blot analysis, there were
no significant changes in Mas expression among all four groups. (Figure
5E)